HRP20171964T1 - Kombinacije i njihova upotreba - Google Patents
Kombinacije i njihova upotreba Download PDFInfo
- Publication number
- HRP20171964T1 HRP20171964T1 HRP20171964TT HRP20171964T HRP20171964T1 HR P20171964 T1 HRP20171964 T1 HR P20171964T1 HR P20171964T T HRP20171964T T HR P20171964TT HR P20171964 T HRP20171964 T HR P20171964T HR P20171964 T1 HRP20171964 T1 HR P20171964T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- sequence
- melphalan
- synergistic combination
- use according
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 4
- 229960001924 melphalan Drugs 0.000 claims 4
- 239000011885 synergistic combination Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1. Sinergistička kombinacija protutijela specifičnog za CD38 koje sadrži HCDR1 sa slijedom GFTFSSYYMN (SEQ ID NO: 1), HCDR2 sa slijedom GISGDPSNTYYADSVKG (SEQ ID NO: 2), HCDR3 sa slijedom DLPLVYTGFAY (SEQ ID NO: 3), LCDR1 sa slijedom SGDNLRHYYVY (SEQ ID NO: 4), LCDR2 sa slijedom GDSKRPS (SEQ ID NO: 5) i LCDR3 sa slijedom QTYTGGASL (SEQ ID NO: 6), te melfalan naznačena time što je namijenjena upotrebi u liječenju multiplog mijeloma.
2. Sinergistička kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što protutijelo sadrži varijabilni teški lanac sa slijedom QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYW GQGTLVTVSS i varijabilni laki lanac sa slijedom DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ.
3. Sinergistička kombinacija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se protutijelo specifično za CD38 i melfalan primjenjuje odvojeno.
4. Sinergistička kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 3, naznačena time što se melfalan primjenjuje prije primjene protutijela specifičnog za CD38.
5. Sinergistička kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 4, naznačena time što se melfalan primjenjuje 72 sata prije primjene protutijela specifičnog za CD38.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705172P | 2012-09-25 | 2012-09-25 | |
| US201361774595P | 2013-03-08 | 2013-03-08 | |
| EP13766523.8A EP2900232B1 (en) | 2012-09-25 | 2013-09-24 | Combinations and uses thereof |
| PCT/EP2013/069858 WO2014048921A1 (en) | 2012-09-25 | 2013-09-24 | Combinations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171964T1 true HRP20171964T1 (hr) | 2018-02-23 |
Family
ID=49237209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171964TT HRP20171964T1 (hr) | 2012-09-25 | 2017-12-19 | Kombinacije i njihova upotreba |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9579378B2 (hr) |
| EP (1) | EP2900232B1 (hr) |
| JP (1) | JP6426093B2 (hr) |
| KR (1) | KR102171669B1 (hr) |
| CN (1) | CN104684552B (hr) |
| AU (1) | AU2013322806C1 (hr) |
| BR (1) | BR112015006731A2 (hr) |
| CA (1) | CA2885792C (hr) |
| DK (1) | DK2900232T3 (hr) |
| ES (1) | ES2658953T3 (hr) |
| HK (1) | HK1210949A1 (hr) |
| HR (1) | HRP20171964T1 (hr) |
| HU (1) | HUE036518T2 (hr) |
| IL (1) | IL237926B (hr) |
| LT (1) | LT2900232T (hr) |
| MX (1) | MX368288B (hr) |
| NZ (1) | NZ706147A (hr) |
| PL (1) | PL2900232T3 (hr) |
| PT (1) | PT2900232T (hr) |
| RU (1) | RU2650618C2 (hr) |
| SG (1) | SG11201502163QA (hr) |
| WO (1) | WO2014048921A1 (hr) |
| ZA (1) | ZA201501980B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0618399B1 (pt) * | 2005-10-12 | 2023-10-03 | Morphosys Ag | Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EA035979B1 (ru) | 2014-09-09 | 2020-09-08 | Янссен Байотек, Инк. | Варианты комбинированной терапии анти-cd38 антителами |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| CA2986594A1 (en) | 2015-05-20 | 2016-11-24 | Tufts Medical Center, Inc. | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| KR20180067693A (ko) | 2015-11-03 | 2018-06-20 | 얀센 바이오테크 인코포레이티드 | 항-cd38 항체의 피하 제제 및 이의 용도 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| KR102427948B1 (ko) | 2016-03-04 | 2022-08-02 | 모르포시스 아게 | 다발성 골수종에서 m-단백질 반응의 임상 평가 |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| KR20200079293A (ko) | 2017-10-31 | 2020-07-02 | 얀센 바이오테크 인코포레이티드 | 고위험 다발성 골수종을 치료하는 방법 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| HUE025369T2 (en) | 2004-02-06 | 2016-02-29 | Morphosys Ag | Human antibodies against CD38 and their use |
| IL296666A (en) | 2005-03-23 | 2022-11-01 | Genmab As | Antibodies against 38cd for the treatment of multiple myeloma |
| EP2799451A1 (en) | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
| BRPI0618399B1 (pt) * | 2005-10-12 | 2023-10-03 | Morphosys Ag | Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica |
| PL2081595T3 (pl) | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| WO2011154453A1 (en) * | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
| CN103118706B (zh) | 2010-09-27 | 2016-05-18 | 莫佛塞斯公司 | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| EP2726477A4 (en) | 2011-06-29 | 2015-08-26 | Harvard College | SMALL MOLECULAR CD38 HEMMER AND USE METHOD THEREFOR |
| ES2808565T3 (es) | 2013-03-13 | 2021-03-01 | Sanofi Sa | Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib |
| AU2013388126B2 (en) | 2013-04-29 | 2019-03-07 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b |
-
2013
- 2013-09-24 DK DK13766523.8T patent/DK2900232T3/en active
- 2013-09-24 CN CN201380050577.7A patent/CN104684552B/zh active Active
- 2013-09-24 LT LTEP13766523.8T patent/LT2900232T/lt unknown
- 2013-09-24 WO PCT/EP2013/069858 patent/WO2014048921A1/en active Application Filing
- 2013-09-24 PT PT137665238T patent/PT2900232T/pt unknown
- 2013-09-24 HU HUE13766523A patent/HUE036518T2/hu unknown
- 2013-09-24 PL PL13766523T patent/PL2900232T3/pl unknown
- 2013-09-24 SG SG11201502163QA patent/SG11201502163QA/en unknown
- 2013-09-24 AU AU2013322806A patent/AU2013322806C1/en active Active
- 2013-09-24 NZ NZ706147A patent/NZ706147A/en unknown
- 2013-09-24 EP EP13766523.8A patent/EP2900232B1/en active Active
- 2013-09-24 US US14/430,801 patent/US9579378B2/en active Active
- 2013-09-24 RU RU2015110981A patent/RU2650618C2/ru active
- 2013-09-24 JP JP2015532454A patent/JP6426093B2/ja active Active
- 2013-09-24 CA CA2885792A patent/CA2885792C/en active Active
- 2013-09-24 BR BR112015006731A patent/BR112015006731A2/pt not_active Application Discontinuation
- 2013-09-24 MX MX2015003589A patent/MX368288B/es active IP Right Grant
- 2013-09-24 KR KR1020157007554A patent/KR102171669B1/ko active IP Right Grant
- 2013-09-24 ES ES13766523.8T patent/ES2658953T3/es active Active
-
2015
- 2015-03-23 ZA ZA2015/01980A patent/ZA201501980B/en unknown
- 2015-03-24 IL IL237926A patent/IL237926B/en active IP Right Grant
- 2015-11-30 HK HK15111752.8A patent/HK1210949A1/xx unknown
-
2017
- 2017-12-19 HR HRP20171964TT patent/HRP20171964T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2900232T3 (pl) | 2018-05-30 |
| JP6426093B2 (ja) | 2018-11-28 |
| LT2900232T (lt) | 2018-02-26 |
| AU2013322806B2 (en) | 2017-11-30 |
| CN104684552A (zh) | 2015-06-03 |
| IL237926A0 (en) | 2015-05-31 |
| ZA201501980B (en) | 2017-11-29 |
| SG11201502163QA (en) | 2015-04-29 |
| US20150238603A1 (en) | 2015-08-27 |
| MX2015003589A (es) | 2015-08-12 |
| CA2885792A1 (en) | 2014-04-03 |
| DK2900232T3 (en) | 2018-02-05 |
| RU2650618C2 (ru) | 2018-04-16 |
| CN104684552B (zh) | 2018-08-07 |
| PT2900232T (pt) | 2018-02-09 |
| EP2900232B1 (en) | 2017-11-15 |
| HK1210949A1 (en) | 2016-05-13 |
| HUE036518T2 (hu) | 2018-07-30 |
| IL237926B (en) | 2020-04-30 |
| CA2885792C (en) | 2021-09-28 |
| RU2015110981A (ru) | 2016-11-20 |
| KR102171669B1 (ko) | 2020-10-30 |
| KR20150090030A (ko) | 2015-08-05 |
| AU2013322806C1 (en) | 2018-03-08 |
| NZ706147A (en) | 2018-10-26 |
| BR112015006731A2 (pt) | 2017-07-04 |
| WO2014048921A1 (en) | 2014-04-03 |
| JP2015530399A (ja) | 2015-10-15 |
| ES2658953T3 (es) | 2018-03-13 |
| AU2013322806A1 (en) | 2015-04-09 |
| MX368288B (es) | 2019-09-27 |
| US9579378B2 (en) | 2017-02-28 |
| EP2900232A1 (en) | 2015-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171964T1 (hr) | Kombinacije i njihova upotreba | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| JP2016520514A5 (hr) | ||
| JP2015530399A5 (hr) | ||
| MX2020001258A (es) | Moduladores del factor del complemento b. | |
| NZ606095A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| PE20150159A1 (es) | Composiciones y metodos para anticuerpos que actuan sobre el factor p | |
| MY166282A (en) | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| EA201201357A1 (ru) | Антитела к cd40 | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| BR112014009866A2 (pt) | formulações de anticorpos e métodos | |
| EP4219718A3 (en) | Compositions and methods for modulating complement factor b expression | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| MX2016008226A (es) | Metodos para el cuidado oral prebiotico usando un sacarido. | |
| PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
| CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
| AR092325A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| NZ631639A (en) | Methods and compositions for treating and diagnosing acute myocardial infarction | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| MX368641B (es) | Compuestos para el tratamiento de inflamación y dolor. |